Protein expression analysis of CML CD34+ cells revealed that Ibr inhibited BTK phosphorylation, while STAT5 activation was not affected, confirming that Bcr-Abl downstream signaling remained unaffected by Ibr. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.